Yüklüyor......
An economic model of long-term use of celecoxib in patients with osteoarthritis
BACKGROUND: Previous evaluations of the cost-effectiveness of the cyclooxygenase-2 selective inhibitor celecoxib (Celebrex, Pfizer Inc, USA) have produced conflicting results. The recent controversy over the cardiovascular (CV) risks of rofecoxib and other coxibs has renewed interest in the economic...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2007
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1925103/ https://ncbi.nlm.nih.gov/pubmed/17610716 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-230X-7-25 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|